- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.10. | Polyrizon Ltd. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 05.10. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.10. | Polyrizon erweitert Patentschutz für nasale Drug-Delivery-Technologie | 4 | Investing.com Deutsch | ||
| 05.10. | Polyrizon Ltd.: Polyrizon Files for U.S. Patent Application to Expand IP Moat Around Intranasal Drug-Delivery Platform | 192 | GlobeNewswire (Europe) | A new patent application covers Polyrizon's proprietary mucoadhesive platform and its potential applications in nasal drug delivery. Raanana, Israel, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd.... ► Artikel lesen | |
| 28.09. | Polyrizon Ltd. GAAP EPS of -$0.79 | 1 | Seeking Alpha | ||
| 28.09. | Polyrizon Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| POLYRIZON Aktie jetzt für 0€ handeln | |||||
| 28.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.09. | Polyrizon enrolls first patient in U.S. allergy blocker trial | - | Investing.com | ||
| 22.09. | Polyrizon Ltd.: Polyrizon Enrolls First Patient in U.S. Clinical Study of NASARIX (PL-14) Allergy Blocker | 171 | GlobeNewswire (Europe) | First patient marks Polyrizon's transition into a clinical-stage company. The U.S clinical study is designed to evaluate the efficacy, safety and tolerability of the NASARIX (PL-14) Allergy Blocker... ► Artikel lesen | |
| 04.09. | Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement | 3 | GlobeNewswire (USA) | ||
| 04.09. | Polyrizon Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.09. | Polyrizon prices $4M registered direct offering | 1 | Seeking Alpha | ||
| 03.09. | Polyrizon Ltd. Announces $4.0 Million Registered Direct Offering and Private Placement | 1 | GlobeNewswire (USA) | ||
| 02.09. | Polyrizon Tumbles on Clinical Studies | 1 | Baystreet.ca | ||
| 02.09. | Polyrizon Ltd.: Polyrizon Completes All Five U.S. Site Contracts for NASARIX First-in-Human Allergy Study | 2 | GlobeNewswire (USA) | ||
| 20.08. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.08. | Polyrizon completes contracting with all five clinical sites | 1 | Investing.com | ||
| 20.08. | Polyrizon Ltd.: Polyrizon Completes Clinical Site Network for NASARIX Study and Advances Toward Patient Enrollment | 1 | GlobeNewswire (USA) | ||
| 13.07. | Polyrizon Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 02.07. | Polyrizon Advances on Test Results | 1 | Baystreet.ca |
1 2 3 4 Weiter >>
64 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,030 | -0,24 % | QIAGEN N.V.: QIAGEN Convenes Global Tuberculosis Experts as New Pressures Challenge Progress Against Tuberculosis | Global TB Summit brings together international experts as persistent disease burden and funding pressures challenge progress against tuberculosis QuantiFERON-TB Gold Plus detects tuberculosis... ► Artikel lesen | |
| VALNEVA | 2,531 | +0,60 % | BRANDMELDUNG: Jetzt wird es für die Valneva-Aktie richtig gefährlich - Handeln Sie vor Montag! | ||
| NOVAVAX | 9,990 | -0,30 % | Novavax: Warum der Großaktionär jetzt zurückweicht | ||
| PALATIN TECHNOLOGIES | 6,010 | -0,17 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| BIOXXMED | 1,000 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| OCUGEN | 0,710 | -0,14 % | Ocugen, Inc. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 0,913 | +3,28 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,490 | -0,18 % | XFRA ET80: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 0,986 | -1,00 % | Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting | Vivoryon Therapeutics N.V. Reports Outcomeof 2026 Annual General Meeting
Halle (Saale) / Munich, Germany, September 29, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 15,020 | -1,31 % | Sarepta shares preclinical data on DM1 treatment candidate | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,512 | -2,10 % | PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| REDHILL BIOPHARMA | 0,495 | 0,00 % | RedHill Biopharma Ltd. - 6-K, Report of foreign issuer | ||
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| PHIO PHARMACEUTICALS | 0,872 | -1,02 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance | Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026)... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 6,100 | 0,00 % | OCULAR THERAPEUTIX, INC - 8-K, Current Report |
POLYRIZON LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,870 (+9,53 %) liegt der Kurs bei 10,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYRIZON LTD finden Sie auf Wallstreet Online.